Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Alterity PBT434 Poster Presented at 2019 MDS Congress

October 3, 2019October 10, 2019 Alterity Therapeutics

Alterity PBT434 Poster – MDS 2019 Congress

Post navigation

Alterity presents clinical data on PBT434 at the 2019 MDS Congress

Quarterly Cash Flow Report

Related Posts

First volunteers dosed in Phase I clinical trial of PBT434, Prana’s lead therapy for parkinsonian diseases

July 3, 2018

Prana Enrolls First Patient in the “Reach2HD” Phase II Huntington Disease Trial

July 17, 2013

AGM 2021 Presentation

November 12, 2021January 5, 2022

Recent Posts

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
Alterity to Present at Life Sciences Investor Forum
Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 – Investing in Healthcare
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065